TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Randomised Efficacy Study of Combination Antimalarials to Treat Uncomplicated Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female, older than 12 months.~* Weight \> 10 kg.~* Diagnoses of pure uncomplicated acute P. falciparum malaria parasitaemia of up to 500 000 asexual parasite/mcl blood with axillary temperature of greater than or equal to 37.5°C or history of fever (defined as within the previous 24 hours).~* Documented informed consent.~* Lives close enough to the study site for reliable follow up.~Exclusion Criteria:~* Has received anti-malarial treatment in the past 7 days.~* Is infected with other malarial species (such subjects may be excluded retrospectively from the analysis).~* Severely ill (based on WHO Criteria for severe malaria ) or if patient is considered, in the opinion of the investigator or designee, to have moderately severe malaria (e.g. prostrate, repeated vomiting, dehydrated) or other danger signs.~* Has received cotrimoxazole, trimethoprim, chloramphenicol, folate or tetracyclines (including doxycycline) in the past 7 days or is likely to require these during the study period.~* History of G6PD deficiency.~* Is pregnant or breastfeeding.~* Has a history of allergy to any of the study drugs (including other sulphonamides e.g. cotrimoxazole, other artemisinin derivatives e.g. co-artemether).~* Serious underlying disease that in the opinion of the clinic team and/or Principal Investigator would make the patient unsuitable for the study in terms of their safety or study analysis.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Continuous non smoker who has not used nicotine containing products for at least 3 months prior to the first dosing and throughout the study, based on screening urine cotinine test.~2. Body Mass Index (BMI) greater than or equal to (\>=) 18.0 and less than or equal to (\<=) 30.0 kilogram per square meter (kg/ m\^2) at screening.~3. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, or ECGs, as deemed by the investigator or designee.~Exclusion Criteria:~1. Positive urine drug or alcohol results at screening and each check in.~2. Positive urine cotinine at screening.~3. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).~4. QT interval with Fridericia's correction (QTcF) interval is \>450 millisecond (msec) or ECG findings are deemed abnormal with clinical significance by the investigator or designee at screening.~5. Estimated creatinine clearance \<90 milliliter per minute (mL/min) at screening.~6. Has been on a diet incompatible with the on-study diet, in the opinion of the investigator or designee, within the 30 days prior to the first dosing and throughout the study.~7. Donation of blood or significant blood loss (example, approximately 500 milliliter \[mL\]) within 56 days prior to the first dosing.~8. Plasma donation within 7 days prior to the first dosing.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Sequence AB: TAK-906 25 mg + TAK-906 25 mg and Rifampin 600 mg (Type: EXPERIMENTAL): TAK-906 25 milligram (mg) (Treatment A), capsule, orally, once on Day 1 of Study Period 1, followed by a washout period of at least 7 days, further followed by rifampin 600 mg, infusion, once, intravenously over 30 minutes along with TAK-906 25 mg (Treatment B), capsule, orally, once immediately after the end of infusion on Day 1 of Study Period 2.
- Sequence BA: TAK-906 25 mg and Rifampin 600 mg + TAK-906 25 mg (Type: EXPERIMENTAL): Rifampin 600 mg, infusion, once, intravenously over 30 minutes along with TAK-906 25 mg (Treatment B), capsule, orally, once immediately after the end of infusion on Day 1 of Study Period 1 followed by a washout period of at least 7 days, further followed by TAK-906 25 mg (Treatment A), capsule, orally, once on Day 1 of Study Period 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label Study to Evaluate the Effect of Every Other Week PROCRIT� (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients (CHAMPS II)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Understand and sign written informed consent~* HIV-infected patients (as documented by HIV-RNA values)~* HIV/HCV co-infected patients not receiving treatment~* Hemoglobin \< 12 g/dL unrelated to transfusion~* Estimated life expectancy of \> 9 months~* Has been maintained on a stable antiretroviral regimen for at least four weeks prior to enrollment into this study.~Exclusion Criteria:~* Acute, symptomatic opportunistic infection or other acute AIDS defining illness~* Anemia attributable to factors other than HIV infection (i.e., iron, B12 or folate deficiencies, hemolysis, gastrointestinal bleeding)~* HCV co-infected patients who are anticipated to receive treatment with ribavirin/interferon during the study period. Previous treatment with ribavirin/interferon must have been completed at least 12 weeks prior to study entry~* Ferritin level \< 40 ng/mL~* Uncontrolled or severe cardiovascular disease including recent (\< 6 months) myocardial infarction, uncontrolled hypertension or congestive heart failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: All-Case Surveillance of Prizbind®

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~Patients who are prescribed with Prizbind® for Intravenous Solution 2.5 g by the discretion of investigators~Exclusion criteria:~None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prizbind® for Intravenous Solution (Type: None): Patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Different Types of Progestin on Sleeping of Menopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* new menopausal patients at Maharaj Nakorn Chiang Mai Hospital~* suitable for estrogen plus progesterone treatment~Exclusion Criteria:~* contraindication for hormone replacement therapy~* recently used sleep enhancing medicine~* recently used psychotic medicine

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- micronized progesterone (Type: EXPERIMENTAL): 1 mg 17 beta-estradiol plus 100 mg micronized progesterone taken orally once a day for 3 months.
- dydrogesterone (Type: EXPERIMENTAL): 1mg 17 beta-estradiol plus 10 mg dydrogesterone taken orally once a day for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Pneumococcal Vaccination Rates in an Ambulatory Pre-surgical Testing Setting

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient seen in out-patient pre-surgical testing center~* At-risk adult patient as defined by the Centers for Disease Control (CDC)~Exclusion Criteria:~* Minors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 110 Years
- Healthy Volunteers: t

Study Arms:
- health education, audit and feedback (Type: OTHER): Focused health education for staff and patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~(1) histology-confirmed metastatic CRC (mCRC); (2) disease progression on standard therapy with at least two lines of chemotherapy, including fluorouracil, oxaliplatin, and irinotecan with or without biologics such as bevacizumab and cetuximab; (3) fruquintinib administered as salvage treatment; (4) available clinical data.~Exclusion Criteria:~(1) lack of follow-up data; (2) fruquintinib administration as second-line treatment; (3) fruquintinib administration stopped after less than two cycles.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- monotherapy group (Type: None): patients received fruquintinib alone
- combine group (Type: None): patients administered fruquintinib in combination with chemotherapy or/and anti-PD1 antibodies

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Practical Telemedicine to Improve Control and Engagement for Veterans With Clinic-Refractory Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Veterans with persistently poorly-controlled type 2 diabetes mellitus defined as the presence of 2 HbA1c values 8.5% during the prior year (none \<8.5%) despite 1 or more appointments with a VHA Primary Care Provider (PCP) or Endocrinology during this period.~Exclusion Criteria:~* age \>70~* life expectancy \<5 years, or other comorbidities that would offset the benefits of HbA1c \<8.5%~* inability to communicate by telephone~* dementia or psychosis~* active alcohol/substance disorder~* pregnancy~* prior hypoglycemic seizure/coma~* refusal to perform self-monitored blood glucose (SMBG)~* use of insulin infusion pumps~* hospitalized for stroke, heart attack or had surgery for blocked arteries in the past 12m~* receiving kidney dialysis~* metastatic cancer diagnosis~* use of a continuous blood glucose monitor (due to HT equipment constraints)~* primary provider requests patient not participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- PRACTICE-DM (Type: EXPERIMENTAL): PRACTICE-DM is a comprehensive telemedicine intervention that bundles telemonitoring, self-management support, diet/activity support, medication management, and depression support - each of which targets a critical factor underlying PPDM - into a single, comprehensive program specifically developed for practical delivery using existing VHA Home Telehealth (HT) workforce, infrastructure, and technical resources.
- Standard VA Home Telehealth (Type: ACTIVE_COMPARATOR): Standard VA HT care coordination and telemonitoring.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Patient completed participation in ENB-002-08 (NCT00744042)~* Written informed consent by parent or other legal guardian prior to any study procedures being performed~* Parent or other legal guardian willing to comply with study requirements~Exclusion Criteria~* History of sensitivity to any of the constituents of the study drug~* Clinically significant disease that precludes study participation~* Enrollment in any study (other than ENB-002-08) involving an investigational drug, device, or treatment for HPP (e.g., bone marrow transplantation)

- Gender: ALL
- Minimum Age: 24 Weeks
- Maximum Age: 42 Months
- Healthy Volunteers: f

Study Arms:
- asfotase alfa (Type: EXPERIMENTAL): An initial single intravenous (IV) infusion of 2 mg/kg asfotase alfa, followed by subcutaneous (SC) injections of 1 mg/kg asfotase alfa 3 times per week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Albuterol HFA MDI in Pediatric Participants With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female child aged 4-11 years, inclusive Asthma of a minimum of six months duration that has been stable for at least four weeks prior to screening.~Exclusion Criteria:~* Hospitalization for acute asthma exacerbation greater than two years in 12 months prior to screening and/or received ER treatment or hospitalization for asthma exacerbation.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Albuterol (Type: EXPERIMENTAL): Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days. HFA-MDI refers to a metered-dose inhaler (MDI) utilizing a hydrofluoroalkane (HFA) propellant.
- Placebo (Type: PLACEBO_COMPARATOR): A placebo of a metered-dose inhaler (MDI) utilizing a hydrofluoroalkane (HFA) propellant. (Hereafter noted as Placebo-HFA-MDI.)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Isovue in Peripheral Digital Subtraction Angiography (DSA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* provides written informed consent;~* at least 18 years of age;~* scheduled to undergo peripheral DSA for the diagnosis and/or treatment of PAOD~Exclusion Criteria:~* pregnant or lactating female;~* known allergies to one more more ingredients in wither product;~* history of severe congestive heart failure (Class IV);~* previously enrolled or received an investigational compound within 30 days;~* history of hypersensitivity to iodinated contrast agents;~* renal impairment eGFR \<60 mL/min/1.73m2, calculated using the MDRD study equation~* any other medical condition decreasing chances of obtaining reliable data

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Isovue 250 (iopamidol) (Type: EXPERIMENTAL): None
- Visipaque 270 (iodixanol) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oxygen for Intrauterine Resuscitation of Category II Fetal Heart Tracings

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Term, singleton patients admitted to Labor\& Delivery for spontaneous labor or labor induction~Exclusion Criteria:~* Multiple pregnancy~* Significant fetal anomalies~* Category III FHT~* Umbilical artery doppler abnormalities~* Maternal hypooxygenation or need for oxygen

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- No Oxygen (Type: EXPERIMENTAL): Room air
- Oxygen (Type: ACTIVE_COMPARATOR): 10L oxygen by nonrebreather mask

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Know the Efficacy of Higher Doses of Pralidoxime in Patients of Organophpsphorus Poisoning.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~-patients with a history of poisoning by an organophosphorus pesticide and clinical features of poisoning.~Exclusion Criteria:~patients who~* were under 12 years~* had chronic disease~* had malignancy~* were pregnant,~* presented more than 24 hrs post-ingestion,~* who could not be resuscitated successfully in the emergency room of our ospital

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatments for Depression: Drug Versus Psychotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Major Depressive Disorder diagnosis~Exclusion criteria:~* Psychotic or bipolar disorder diagnosis~* Substance dependence in the last 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 Sertraline/Venlafaxine (Type: EXPERIMENTAL): Participants receive sertraline for the first 8 weeks. Participants will receive venlafaxine if they do not respond to sertraline by week 8
- 2 Supportive Expressive Therapy (Type: ACTIVE_COMPARATOR): Participants will receive supportive-expressive psychotherapy.
- 3 Pill Placebo (Type: PLACEBO_COMPARATOR): Participants receive placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trachoma Amelioration in Northern Amhara (TANA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~• All residents residing in the state-teams which are randomly selected for this study.~Exclusion Criteria:~* Pregnant women~* Children under 6 months of age~* All those who are allergic to macrolides or azalides~* Refusal of village chief (for village inclusion), or refusal of parent or guardian (for individual inclusion)~Individuals in these three exclusion criteria will not be given the study antibiotic azithromycin, but offered the current WHO-recommended alternative treatment to azithromycin for active trachoma, which is 1% tetracycline eye ointment, to be used twice a day, topically to both eyes, for six weeks. Note that the exclusion criteria refer to the exclusion to the treatment drug, but not to the monitoring, treatment of trachoma, and examinations.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- A (Type: OTHER): Annual mass treatment
- B (Type: OTHER): Biannual mass treatment
- C (Type: EXPERIMENTAL): Mass administration of antibiotic; treatment of children (1-10 years of age) only
- D (Type: NO_INTERVENTION): Delayed initiation of mass administration of antibiotic
- F (Type: OTHER): One-time mass administration only
- G (Type: EXPERIMENTAL): One-time mass administration of antibiotics, plus intensive latrine construction

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete